Checkpoint-based therapies may sensitize patients to subsequent therapies.
Randomized clinical trial showed significant improvement in overall survival with glasdegib.
Researchers investigated the safety and efficacy of combination therapy with azacytidine and nivolumab for relapsed/refractory AML.
Researchers reviewed cancer incidence in patients with Diamond-Blackfan anemia.
A meta-analysis of 14 randomized, controlled trials was conducted to determine if combining G-CSF with intensified chemotherapy improved overall survival.
The Effect of Intravenous Hydration Strategy on Plasma Methotrexate Clearance During Intravenous High-dose Methotrexate Administration in Pediatric Oncology Patients
[Cancer Management and Research] Researchers sought to determine the effect of intravenous hydration on plasma methotrexate clearance on pediatric oncology patients receiving HD-MTX for ALL, NHL, or osteosarcoma.
Stem Cell Transplantation Superior to Chemotherapy for Relapsed/Refractory DLBCL, Follicular Lymphoma
A review of therapy options for relapsed/refractory DLBCL and FL compared SCT with chemotherapy/immunotherapy and experimental regimes. Patients fared better with SCT than other treatment modalities.
A retrospective evaluation of patients treated at a tertiary cancer center demonstrated that patients with Hodgkin lymphoma experienced periods of actionable distress in survivorship, despite a low overall distress burden.
A snapshot of an international Commission's report on the issues inherent with adverse event reports of hematologic malingnancies in clinical trials.
A prospective cohort study from Denmark investigated the link between maternal hormonal contraception use before — more than 3 months and within 3 months — and during pregnancy and risk of leukemia in their children.
In a retrospective evaluation, investigators sought to identify risk factors for higher-grade transformation in patients with marginal zone lymphomas.
Although brentuximab vedotin offers clinical benefit over bleomycin in first-line treatment of adults with advanced Hodgkin lymphoma, investigators find the drug is not cost-effective.
A nurse-led study explored the significance of nurse navigators for patients with lymphoma approaching their transition from acute care to survivorship care.
Increased risk of on-therapy relapse, relapse after completing therapy versus children with ALL
A retrospective follow-up study demonstrates that tandem autologous-allogeneic is safe for standard and high-risk multiple myeloma. However, benefits do not extend to patients with ultra-high-risk disease and those with disease progression after autologous HCT.
BMI often relies on self-reported weight and height values, and therefore may be a less accurate predictor of cancer risk than alternative body composition measurements.
A substudy of a multinational study sought to determine the risk to ovarian function with ABVD, AVD, and BEACOPP regimens on ovarian function in women with Hodgkin lymphoma.
A retrospective study of platelet- and infection-related data from patients with ITP revealed the influence platelet levels have on infections as well as efficacy of transfusions.
The family and friends of a patient diagnosed with blood cancer are often eager to help but unsure how to go about it. This article offers 8 practical tips oncology nurses can share with caregivers.
An international multidisciplinary panel of experts in pediatric oncology and infectious diseases convened to develop recommendations for the prevention and treatment of C difficile infection in pediatric patients with cancer or who are undergoing HSCT.
Lumoxiti, a CD22-directed cytotoxin, has been approved for adult patients who have had at least two prior therapies for the disease.
In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.
A retrospective study evaluated the efficacy vs pulmonary toxicity of brentuximab vedotin for relapsed or refractory Hodgkin lymphoma in pediatric patients.
A retrospective analysis of outcomes demonstrated the influence of rituximab maintenance after R-CHOP or R-CVP for follicular lymphoma in elderly patients.
Outcomes data demonstrated the impact of socioeconomic status and insurance coverage on outcomes for patients with follicular lymphoma by age (younger than 65 and 65 and older).
Researchers found that stable responses occurred in 18 percent of patients on fostamatinib, versus 2 percent on placebo.
Using a longitudinal parallel-process model, researchers evaluated the impact of physical activity on symptoms, physical activity, and cognitive function in children with ALL undergoing chemotherapy.
Researchers sought to determine if the newly formed regimen RiBVD was effective and tolerable in patients older than 65 with mantle cell lymphoma.
A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.
A phase 2 study was conducted to determine the effectiveness of adding lenalidomide to R-CHOP as a first-line treatment for high-burden follicular lymphoma.
Ibrutinib monotherapy may reduce the need for chemotherapy for some treatment-naive patients with chronic CLL, research indicates.
In this retrospective study, researchers assessed the outcomes of 88 patients with hematologic disease who underwent HSCT.
Findings in an ongoing phase 2 trial demonstrate that a sequential regimen of these agents has significant potential to improve depth of response and outcomes for patients with chronic lymphocytic leukemia.
A single-center retrospective study assessed the effectiveness of serum albumin levels and BMI as prognostic measures in patients with AML.
Researchers sought to determine if NMA or reduced-intensity conditioning with busulfan improved severity/duration of oral mucositis compared with myeloablative conditioning in patients with hematologic cancer undergoing HCT.
The manufacturer of daratumumab, a CD38-directed antibody for the treatment of multiple myeloma, has submitted a sBLA and a type II variation to the US FDA and European Medicines Agency, respectively, for approval of a split dosing regimen.
In an open-label study, researchers sought to determine the optimal amount of bed rest after intrathecal chemotherapy for patients with hematologic cancers.
A population study of a PETALE cohort demonstrated an association between functional health domains and psychological risk in adolescent and adult survivors of cALL.
Mogamulizumab-kpkc (Poteligeo), a humanized monoclonal antibody that targets CCR4, provides a new treatment option for patients with MF and is the first FDA-approved therapy for SS.
Researchers sought to determine the impact of intensive chemotherapy on achieving complete remission and overall survival among patients with MDS or sAML.
US FDA issues a recommendation on use of azithromycin in patients with hematologic malignancies who have undergone HSCT.
Study sought to determine the health-related QOL and posttraumatic stress symptoms in adolescent and young adult cancer survivors post-HSCT compared with their healthy peers.
A retrospective chart review was conducted to determine if adding lorazepam to granisetron would improve CINV prevention in pediatric patients with newly diagnosed ALL.
Fertility Preservation in Hodgkin's Lymphoma Patients That Undergo Targeted Molecular Therapies: An Important Step Forward From the Chemotherapy Era
[Cancer Management and Research] A review of fertility complications induced by chemotherapy and radiotherapy, as well as possible treatment options for HL patients with fertility problems.
Treatment options for von Willebrand Disease (VWD).
A new analysis of FAB/LMB 96 looked into factors associated with shortened OS among children and adolescents with B-NHL.
Although involved-field radiotherapy (IFRT) has a high level of disease control in patients with follicular lymphoma, relapse frequently occurs; therefore, researchers sought to determine if adding chemotherapy would improve progression-free survival.
In this study, researchers investigated the effects of exercise on physical and psychological recovery after autoHSCT for multiple myeloma.
De-escalation of TKI therapy may be an effective management strategy among patients with CML who have responded to therapy.
A retrospective study sought to evaluate outcomes for patients with CLL who were treated with FCR, a highly effective treatment, and initially had refractory disease, experienced relapse early, or were unable to complete therapy due to toxicity.
In this study, researchers assigned 75 patients with newly diagnosed Philadelphia chromosome (Ph)-positive CML-CP to receive dasatinib 50 mg once daily.
Patients with hematologic cancers often require a combination of inpatient and outpatient care. The oncology nurse navigator is an ideal care provider to help patients manage their care and transitions between care settings, according to a presentation at the 2018 ONA Navigation Summit.
Andrographolide Potentiates the Antitumor Effect of Topotecan in Acute Myeloid Leukemia Cells Through an Intrinsic Apoptotic Pathway
[Cancer Management and Research] In this study, researchers explored the potential of andrographolide and topotecan, separately and together, in the in vitro treatment of the U937 acute myeloid leukemic cell line.
Results of a prospective phase 3 study demonstrated noninferiority of R-THP-COP for diffuse large B cell lymphoma to the standard of care, suggesting the regimen may be an alternative option for these patients.
In a prospective, longitudinal study, researchers investigated the potential for quality of life, fatigue, and physical functioning to return to previous levels in patients with AML after treatment.
FDA approval was based on results of the single-arm phase 2 JULIET clinical trial.
An assessment of more than 71,000 patients with leukemia demonstrated the difference in outcomes for patients admitted to hospital on the weekend vs weekday. Findings were presented at the 2018 ASCO Annual Meeting.
A review of current options and ongoing trials for managing ARIE, a common esophageal adverse effect caused by radiotherapy to the thoracic region for lung, breast, or head and neck cancers, or lymphoma.
Children's Oncology Group study reported on the effect of dexrazoxane on cardiotoxicity of anthracycline-containing regimens in pediatric patients with AML at the 2018 ASCO Annual Meeting.
Duvelisib, a first-in-class dual inhibitor of PI3K-delta and -gamma, was evaluated in patients with relapsed/refractory CLL/SLL and in patients with refractory indolent non-Hodgkin lymphoma.
Consultations for palliative care for hospitalized highly symptomatic patients with cancer is low regardless of curability or whether patient has hematologic or solid cancer, a study presented at 2018 ASCO has shown.
The ability to make early adjustments to treatment has the potential to improve survival.
A newly developed web site, described in a presentation at the 2018 ONS Annual Congress, aims to help nurses and patients explore clinical trial options for patients with hematologic cancers.
Teaming up with multiple specialists to create an algorithm for managing AML in older patients improved clinician knowledge as well as provided patient-centered care, a presentation at 2018 ONS Annual Congress has shown.
Researchers assessed the effectiveness of low level laser therapy in preventing or minimizing oral mucositis in patients with hematologic cancers preparing to undergo HSCT. Results were presented at the 2018 ONS Annual Congress.
Results of a prospective, longitudinal study presented at 2018 ONS Congress demonstrate improvement from baseline to discharge patients with acute leukemia who receive induction chemotherapy in hospital.
Accelerated approval was granted by the FDA based on the results of a single-arm trial.
A presentation at 2018 ONS Congress described the success of a class focused on preparing patients and their families to management their care after discharge.
Patients with lymphoma were interviewed to determine their evaluation of a program that offered continuing clinical care with a nurse-led intervention in the early months of survivorship.
[Cancer Management and Research] A review of marginal zone lymphomas, a common and varied group of hematologic malignancies, and their treatment, with a focus on the Bruton's tyrosine kinase ibrutinib.
A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.
A group of Australian researchers report study findings that demonstrate a significant improvement in PFS in patients with relapsed/refractory CLL treated with venetoclax plus rituximab compared with the standard care.
Slight changes in taste perceptions are noted in patients undergoing HSCT for hematologic cancers. In this study, researchers sought to determine how these changes affect quality of life and nutritional intake.
FDA approval was granted based on findings from the open-label phase 3 ECHELON-1 study.
Researchers conducted a retrospective study to assess 18F-FDG PET/CT vs bone marrow biopsy to detect bone marrow involvement among pediatric patients with Hodgkin lymphoma.
Researchers compared survival outcomes of thiotepa-based intensified RIC vs standard RIC among patients undergoing cord-blood transplantation (CBT).
A study of 133 patients with multiple myeloma who experienced a first relapse compared the efficacy of long-term therapy lenalidomide alone vs with dexamethasone.
A report on how variations in the effects of geriatric syndromes and aging can affect treatment modality choices and outcomes for the eldest older adults with hematologic cancers.
Study data suggest that cognitive impairments may be associate with worse survival among patients with hematologic cancer.
The US FDA granted approval to fostamatinib (Tavalisse), a kinase inhibitor, for the treatment of thrombocytopenia in patients with chronic IPT who have had an insufficient response to a previous treatment.
In a case-control study using PEDS data, researchers determined the impact of inactivity on risk for Hodgkin lymphoma and non-Hodgkin lymphoma.
Bax, Bcl-2, and Bax/Bcl-2 as Prognostic Markers in Acute Myeloid Leukemia: Are We Ready for Bcl-2-Directed Therapy?
[Cancer Management and Research] This report presents an assessment of the relationship of Bax/Bcl-2 expression and the clinical response of patients with AML treated with cytarabine plus daunorubicin, and their potential as biomarkers to predict chemotherapeutic outcomes.
The ALLIVE trial sought to determine if eLPI levels were predictive of iron-related toxicity and mortality after HCT in patients with AML or MDS.
Although many TKIs have well-documented cardiotoxic effects, results of a single-center prospective study that assessed effects of 1 year of therapy with imatinib or nilotinib in patients with CML demonstrated safety and efficacy of the 2 agents in this population.
This study examined the risk of secondary cancers among patients with CML who were treated with TKIs.
The US FDA approved expanding the indications for the agent to include pediatric and adult patients with B-cell precursor ALL who have minimal residual disease during or after treatment.
In a study from the Cleveland Clinic, researchers investigated the association between well-differentiated thyroid cancer and risk for AML or CML in those patients treated with radioactive iodine.
Inotuzumab ozogamicin (InO) use may have quality of life benefits for patients with R/R B-cell ALL, as well as producing improved clinical outcomes.
Based on results of 2 prospective studies, the FDA approved the use of nilotinib in pediatric patients older than 1 year with newly diagnosed Ph+ CML-CP and those with TKI-intolerant or resistant disease.
A cross-sectional study asked patients with hematologic cancers to name the components of care they felt were most crucial to their perception of optimal care.
Some patients with chronic myeloid leukemia in chronic phase maintained TFR after receiving nilotinib, according to data from the ENESTfreedom study.
Researchers investigated the antileukemic activity of metformin and ruxolitinib alone and in combination in patients with myeloproliferative neoplasms.
A retrospective study evaluated timing, frequency, dosing, and other factors related to bisphosphonate therapy in patients with multiple myeloma.
Researchers used mouse cells to determine activation levels of FcγRIIIa and FcγRI using obinutuzumab, rituximab and ofatumumab.
Results of the ENESTop study demonstrate the potential for patients with CML who had deep molecular response to achieve long-term treatment-free remission (TFR) after second-line nilotinib, increasing the focus of TFR as a therapeutic outcome.
Researchers present findings of a study assessing the value of SESM evaluations in patients with hematologic cancer prior to undergoing SCT at the NACNS 2018 Annual Conference.
Idiopathic thrombocytopenic purpura (ITP) may be linked to an increased risk of cardiovascular disease, but studies have not been conclusive.
What are key monitoring guidelines for patients with CLL being treated with venetoclax?
A study from South Korea determined the prevalence and type of CAM practices lymphoma survivors used for various purposes including ease symptoms, augment treatment, boost immunity, and gain a sense of control.
A review of management approaches to Hodgkin lymphoma in Europe vs the United States/North America demonstrates that although some differences exist, worldwide studies that would enhance patient outcomes are feasible.
Sign Up for Free e-newsletters
- Cancer Treatment and Research: What Lies Ahead in 2019
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Continuous Therapy May Be Beneficial in Patients With Newly Diagnosed Multiple Myeloma
- Regular Physical Activity — Even Initiated Postdiagnosis — Improves Survival for Cancer Patients
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Brain Exercise Program Eases Chemobrain in Breast Cancer Survivors
- Hormone Therapy for Breast Cancer (Fact Sheet)
- Counseling on the Dangers of Vaping
- Radical Prostatectomy vs Active Surveillance: Results of Nearly 3 Decades of Follow-up
- Potential of Fecal Microbiota Transplantation in Managing Immunotherapy-Associated Colitis
- Ixazomib Maintenance After ASCT Improves Progression-Free, Overall Survival in Multiple Myeloma
- Evolutionary Role of Chemotherapy in Advanced Nasopharyngeal Carcinoma: A Literature-based Network Meta-analysis
- Helping Patients Face the Challenge of Eating Healthy During Cancer Treatment
- Gastrointestinal Perforation Complicates Management of Mantle Cell Lymphoma
- Modernizing Eligibility Criteria Could Increase Access to, Participation in Clinical Trials
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|